title: Five years' experience with thymoglobulin induction in a pediatric renal transplant population.
abstract: Antibody induction therapy is used in the majority of pediatric patients undergoing renal transplantation. Our center has previously reported short-term outcomes with TMG as induction therapy. We now present our experience over the last five yr. Patients received TMG intra- and post-operatively at a dose of 1.5 mg/kg/day. The dose was decreased to 0.75 mg/kg/day or held dependent on the patient's WBC and platelet counts. Post-transplant immunosuppression also included corticosteroids, MMF, and either TAC or CSA. Patient and graft survival, number of acute rejection episodes, creatinine clearance, incidence and type of infections, and trough levels of calcineurin inhibitor drugs were monitored during the follow-up period. Thirty-four renal transplants were performed in 33 pediatric patients ranging in age from 1.7 to 17.8 yr. Seventeen rejection episodes occurred during the time of follow-up with three patients having more than one episode, but only three episodes occurred within the first year after transplantation. Three patients had graft loss in the first week after transplantation from primary non-function (1) or technical failure/thrombosis (2). Graft losses occurred in seven additional patients during the time of follow-up with the first loss occurring at 17.7 months. Among patients with functional grafts at one wk after transplant, graft survival at one and three yr was 100% and 73% respectively. There were no patient deaths. There were no cases of post-transplant lymphoproliferative disease or other malignancy. One patient had symptomatic CMV disease. TMG is safe and effective as induction therapy in pediatric renal transplant patients. Late graft loss remains a challenge in the pediatric patient population, particularly in adolescents.
authors.affiliation: Department of Pediatrics, The University of Tennessee Health Science Center, Memphis, TN, USA.
authors.forename: M
authors.initials: M
authors.lastname: Colleen Hastings
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Wyatt
authors.forename: Keith K
authors.initials: KK
authors.lastname: Lau
authors.forename: Deborah P
authors.initials: DP
authors.lastname: Jones
authors.forename: Sandra L
authors.initials: SL
authors.lastname: Powell
authors.forename: Dena W
authors.initials: DW
authors.lastname: Hays
authors.forename: Lillian W
authors.initials: LW
authors.lastname: Gaber
authors.forename: A
authors.initials: A
authors.lastname: Osama Gaber
authors.forename: Bettina H
authors.initials: BH
authors.lastname: Ault
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000961:Antilymphocyte Serum; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007674:Kidney Diseases / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; C512542:thymoglobulin